Medication

Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Essential, Partnership, Risk, Patient, Conditional sentence, Medication, Pharmaceutical industry

This strategic collaboration aims to address unmet commercial and medical needs by allowing AcedrA to register, promote, and commercialize a portfolio of 36 Essential Medicines across various therapeutic areas within 12 countries in the Middle East and North Africa Region.

Key Points: 
  • This strategic collaboration aims to address unmet commercial and medical needs by allowing AcedrA to register, promote, and commercialize a portfolio of 36 Essential Medicines across various therapeutic areas within 12 countries in the Middle East and North Africa Region.
  • Essential Pharma specializes in ensuring sustainable access to clinically differentiated, low-volume, and difficult-to-manufacture medicines for chronic diseases and acute care.
  • As a global leader in acquiring, integrating, and maintaining Essential medicines at risk of shortages or discontinuation, Essential Pharma works collaboratively with partners worldwide to uphold the highest standards of pharmaceutical manufacturing.
  • Emma Johnson, CEO of Essential Pharma, commented: “As we continue our mission to provide sustainable access to vital medicines, we are thrilled to announce our partnership with AcedrA BioPharmaceuticals.

The API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. Soil

Retrieved on: 
Tuesday, April 9, 2024
Manufacturing, Retail, White House, Federal Government, Pharmaceutical, Research, Oncology, Supply Chain Management, Foundation, Science, Philanthropy, Public Policy, Government, Clinical Trials, General Health, Biotechnology, Health, Healthcare Reform, Health Technology, Chemicals, Plastics, Growth, Medication, Environment, Partnership, Lomustine, Patient, Pharmacy, Economic development, Cancer, Glioblastoma, Investment, API, Soil, Pharmaceutical industry

“Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.

Key Points: 
  • “Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.
  • "The St. Louis region is at the forefront of emerging technologies and API production,” said Sen. Brian Williams, D- St. Louis.
  • In 2023, the API Innovation Center was awarded $9.5 million from the Missouri Technology Corporation’s Advanced Manufacturing Resiliency Grant Program.
  • With this support, the API Innovation Center is investing in building a regional hub for drug advanced manufacturing, establishing Missouri as a leader in domestic API production to secure the U.S. essential drug supply chain.

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Retrieved on: 
Monday, April 8, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Wolfram syndrome, Medication, Metabolism, Patient, AMX0035, Samuel, Immunology, Doctor of Philosophy, MD, Trial of the century, Amylyx Pharmaceuticals, Division, Disorder, Pathology, Pharmaceutical industry

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Key Points: 
  • A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.
  • Dr. Fumihiko Urano is a physician and medical researcher specializing in Wolfram syndrome.
  • Dr. Urano is a driving force in the study of Wolfram syndrome and related disorders, including WFS1-related disorders/Wolfram-like disorders.
  • As director of the Wolfram Syndrome Clinic and the Wolfram Syndrome International Registry & Clinical Study at Washington University, Dr. Urano treats patients with Wolfram syndrome and related disorders, and leads basic science, clinical, translational, and interventional studies of Wolfram syndrome and related disorders.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Bluesight Hospital Pharmacy Operations Report Reveals Streamlining Purchasing is Top Priority in 2024

Retrieved on: 
Tuesday, April 9, 2024
Medication, Hospital, Software, Ground substance, Pharmacy, Pharmacist, Health, Nursing

ALEXANDRIA, Va., April 9, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, unveiled the findings of its 10th annual Hospital Pharmacy Operations Report (HPOR) .

Key Points: 
  • ALEXANDRIA, Va., April 9, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, unveiled the findings of its 10th annual Hospital Pharmacy Operations Report (HPOR) .
  • Streamlining pharmacy operations remains a priority, driven by the need to combat drug shortages and ensure compliance.
  • Pharmacists report that inflation, an increase in shortages, and recalls are generating a new system-wide focus on optimizing purchasing operations.
  • The 10th annual Hospital Pharmacy Operations Report (HPOR) presents a detailed examination of the prevailing trends influencing hospital operations and pharmacy management across the United States in 2024.

Nova Industrial Analytics: Unveiling a New Era in Process Analytical Technology

Retrieved on: 
Tuesday, April 9, 2024
Quality control, Growth, Medication, Software, Fossil fuel, Safety, Oil, Analytica, Industrial design

"The rebranding to Nova Industrial Analytics is not just a change of name, but a reflection of our expanded mission to leverage advanced analytics in industrial applications," says Stefan Beck, CEO of Nova Industrial Analytics.

Key Points: 
  • "The rebranding to Nova Industrial Analytics is not just a change of name, but a reflection of our expanded mission to leverage advanced analytics in industrial applications," says Stefan Beck, CEO of Nova Industrial Analytics.
  • It also features a resource hub for clients and partners seeking to enhance their understanding of process analytical technology and its applications.
  • "Our decision to evolve into Nova Industrial Analytics is driven by our vision to push the boundaries of what is possible in industrial analytics," Beck added.
  • Nova Industrial Analytics, with its team of seasoned experts and global presence, is poised to lead the charge in transforming industrial processes through innovative analytical technologies.

Brillio Welcomes Ashish Singh to its Board of Directors

Retrieved on: 
Monday, April 8, 2024
Growth, Medication, Health, Media, Therapy, Partner, Bain & Company, Entertainment

DALLAS, April 8, 2024 /PRNewswire/ -- Brillio, one of the fastest growing digital technology service providers, today announced that Ashish Singh has been appointed to the company's Board of Directors to help bolster its strategy, especially for the healthcare vertical. Boston-based Singh is currently an Advisory Partner in Bain & Company, and joins the Brillio Board with more than three decades of consulting experience spanning multiple industries, his primary focus being healthcare.

Key Points: 
  • Boston-based Singh is currently an Advisory Partner in Bain & Company, and joins the Brillio Board with more than three decades of consulting experience spanning multiple industries, his primary focus being healthcare.
  • At Bain, Singh led the founding of many of the company's practice areas, including Pharmaceuticals, Enterprise Software, and Media & Entertainment.
  • He has served two terms on Bain's global Board of Directors, and has also served as the Global Practice Leader for Bain Healthcare.
  • "I am excited to join the Brillio board," said Ashish Singh.

Brillio Welcomes Ashish Singh to its Board of Directors

Retrieved on: 
Monday, April 8, 2024
Growth, Medication, Health, Media, Therapy, Partner, Bain & Company, Entertainment

DALLAS, April 8, 2024 /PRNewswire/ -- Brillio, one of the fastest growing digital technology service providers, today announced that Ashish Singh has been appointed to the company's Board of Directors to help bolster its strategy, especially for the healthcare vertical. Boston-based Singh is currently an Advisory Partner in Bain & Company, and joins the Brillio Board with more than three decades of consulting experience spanning multiple industries, his primary focus being healthcare.

Key Points: 
  • Boston-based Singh is currently an Advisory Partner in Bain & Company, and joins the Brillio Board with more than three decades of consulting experience spanning multiple industries, his primary focus being healthcare.
  • At Bain, Singh led the founding of many of the company's practice areas, including Pharmaceuticals, Enterprise Software, and Media & Entertainment.
  • He has served two terms on Bain's global Board of Directors, and has also served as the Global Practice Leader for Bain Healthcare.
  • "I am excited to join the Brillio board," said Ashish Singh.

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Retrieved on: 
Friday, March 22, 2024
Retina, Medication, SAN, NDA, Adolescence, Clinical trial, Safety, Pharmacokinetics, PMDA, Therapy, DRAGON, Pharmaceutical industry

In the Phase 2 trial, 42% of Tinlarebant-treated subjects (5 out of 12) did not develop atrophic retinal lesions during the 24-month treatment period

Key Points: 
  • In the Phase 2 trial, 42% of Tinlarebant-treated subjects (5 out of 12) did not develop atrophic retinal lesions during the 24-month treatment period
    SAN DIEGO, March 22, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces its submission to the Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a clinical trial of Tinlarebant in adolescent STGD1 in Japan (“DRAGON II”).
  • The DRAGON II trial is a combination of Phase 1b open-label study to evaluate the pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese adolescent STGD1 subjects and a Phase 2/3, global, multicenter, double-masked, placebo-controlled, randomized study designed to evaluate the efficacy, safety and tolerability of Tinlarebant in adolescent STGD1 subjects.
  • Approximately 60 subjects, aged 12 to 20 years old, including approximately 10 Japanese subjects, are targeted for enrollment in the Phase 2/3 portion of the trial with a 1:1 randomization (tinlarebant:placebo).
  • The data from Japanese subjects is intended to facilitate future NDA applications in Japan.